Race Oncology Ltd. | Balance Sheet

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Cash & Short Term Investments
48.30
21.30
4,349.30
1,696.80
3,710.00
Total Accounts Receivable
13.50
103.20
109.80
1.80
0.40
Other Current Assets
-
-
10.40
52.20
30.80
Total Current Assets
61.80
124.50
4,469.50
1,750.90
3,741.30
Intangible Assets
-
-
-
4,250.00
4,499.10
Total Assets
61.80
124.50
4,469.50
6,000.90
8,240.40
ST Debt & Current Portion LT Debt
-
-
5.20
-
-
Accounts Payable
132.00
118.80
107.20
192.60
205.10
Other Current Liabilities
-
-
279.20
170.90
104.60
Total Current Liabilities
132.00
118.80
391.60
363.60
309.70
Total Liabilities
132.00
118.80
391.60
363.60
309.70
Common Equity (Total)
70.20
5.70
4,077.90
5,637.30
7,930.70
Total Shareholders' Equity
70.20
5.70
4,077.90
5,637.30
7,930.70
Total Equity
70.20
5.70
4,077.90
5,637.30
7,930.70
Liabilities & Shareholders' Equity
61.80
124.50
4,469.50
6,000.90
8,240.40

About Race Oncology

View Profile
Address
710 Collins Street
Docklands Victoria (VIC) 3008
Australia
Employees -
Website http://www.raceoncology.com
Updated 07/08/2019
Race Oncology Ltd is a pharmaceutical company, whose business model is to pursue later stage drug assets, principally in the cancer field. Its first important asset is a chemotherapy drug, called Bisantrene, which is used as the first line of treatment for Acute Myeloid Leukaemia and many other cancers. The company was founded on February 15, 2011 and is headquartered in Docklands, Australia.